– On track for first Biologics License Application (BLA) approved cell therapy in lead indication relapsed/refractory AL Amyloidosis – ...

M. Buchanan est l’ancien directeur financier et directeur des opérations de Silk Road Medical, où il a développé avec succès une entreprise de dispositifs médicaux en phase de croissance, aboutissant ...

The NADP Foundation expects to fund two to three projects in 2025 with a maximum award of $50,000 for each project. The proposals are due Oct. 1, and the Foundation expects to announce awards on Dec.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, ...

The Company also announced that its management team plans to present and meet with investors at the following upcoming investor conferences: ...

Additional information about the reverse stock split can be found in the definitive proxy statement filed with the Securities and Exchange Commission (SEC) on June 10, 2025, which is available on the ...

Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an ...

In addition, Fractyl granted the underwriters a 30-day option to purchase up to an additional 2,857,142 shares of common stock, along with associated Tranche A and Tranche B Warrants, at the public ...

Francisco Javier Duran, Chief Executive Officer of Durgalab, added, “We are confident in bringing FemBloc to Spain, supported by its positive safety profile and compelling value proposition. FemBloc ...

– Company to Host Conference Call on August 13, 2025, at 4:30 p.m. ET – ...

FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion. NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ( ...

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced ...